Eli Lilly, WuXi Biologics and Alexandria-backed cancer and orphan disease therapy developer Inhibrx has received $40m in funding from Viking Global Investors.
Inhibrx, a US-based biologic drug developer backed by corporate investors Eli Lilly and WuXi Biologics, raised $40m in convertible promissory note financing from hedge fund Viking Global Investors on Tuesday.
Originally known as Tenium Therapeutics, Inhibrx has developed a protein engineering platform, SdAb, that is capable of generating treatments addressing complex diseases.
The company is focusing its efforts on cancer and orphan conditions, such as Alpha-1, an inherited disorder that can lead to lung and liver diseases. It also hopes…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
